Boiron (FRA:BON) Quality Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:BON Boiron SA FRA:BON
75 GF Score
Price €26.60
GF Value €33.56
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Boiron Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Boiron Quality Rank Related Terms

FRA:BON
75GF Score
Boiron SA FRA:BON
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Boiron (FRA:BON) Overvalued in 2026?

Based on GuruFocus' analysis, Boiron stock appears to be undervalued. The current stock price of €26.60 is trading 20.7% below its estimated GF Value™ of €33.56. GuruFocus considers Boiron to be Modestly Undervalued.

Key valuation signals for FRA:BON:

  • Quality Rank:
  • GF Value™: €33.56 vs. price of €26.60 (20.7% below fair value)
  • GF Score™: 75/100 with 4 warning signs

No single metric tells the full story. See the FRA:BON stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Boiron Business Description

Other Exchanges BOIRF:USA0DTF:UKBOI:France
Address 2, Avenue de l’Ouest Lyonnais No. 039, Messimy, FRA, 69510
Boiron SA is a drug manufacturer that focuses on homeopathic products. The company's revenue is roughly split between its nonproprietary homeopathic medicines and products in its over-the-counter specialties category. Boiron's nonproprietary medicines are generic products that do not refer to any therapeutic indication, while the specialties category includes first-resort products provided in tablet form, are bottled to use as drops, syrups, or ointments. Geographical segments are France, Europe, North America, and other countries. It generates a majority of revenue from France. The company's products include Oscillococcinum, Stodal and Stodaline, Arnigel, Camilia, Sedatif PC, Coryzalia, Homeoptic, and Homeovox.
75GF Score

Get the complete analysis for FRA:BON

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€26.60
Price
€33.56
GF Value